Market open

Adicet Bio/$ACET

14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX

About Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Ticker

$ACET
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Boston, United States

Employees

143
Website
www.adicetbio.com

Adicet Bio Metrics

BasicAdvanced
$75M
-
-$1.55
1.70
-

$75M

1.7

$3.62

$0.81

575K

10.638

10.43

7.054

8.603

-42,812.67%

-33.50%

-58.04%

0.35

0.35

-0.744

-53.42%

-8.30%

What the Analysts think about Adicet Bio

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Adicet Bio stock.

Adicet Bio Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Adicet Bio Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Adicet Bio News

AllArticlesVideos
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire·2 weeks ago
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire·2 months ago
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACET

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Adicet Bio stock?

Adicet Bio (ACET) has a market cap of $75M as of January 15, 2025.

What is the P/E ratio for Adicet Bio stock?

The price to earnings (P/E) ratio for Adicet Bio (ACET) stock is 0 as of January 15, 2025.

Does Adicet Bio stock pay dividends?

No, Adicet Bio (ACET) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Adicet Bio dividend payment date?

Adicet Bio (ACET) stock does not pay dividends to its shareholders.

What is the beta indicator for Adicet Bio?

Adicet Bio (ACET) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.